Celltrion Healthcare Competitors and Similar CompaniesClear all

Celltrion Healthcare's competitors and similar companies include CureVac, Candel Therapeutics, Amolyt Pharma and OBI Pharma.
Celltrion Healthcare
Celltrion Healthcare
Celltrion Healthcare is a biopharmaceutical company specializing in oncology, influenza, psoriasis, and arthritis.,
CureVac
CureVac
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
Candel Therapeutics
Candel Therapeutics
Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies.
Amolyt Pharma
Amolyt Pharma
Amolyt Pharma (formerly known as Alizé Pharma) is a company that specializes in the development of biopharmaceutical drugs, proteins, and peptides for the treatment of metabolic diseases and cancer.
OBI Pharma
OBI Pharma
OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics.
Founding Date
Founding Date
2002
Founding Date
2000
Founding Date
1999
Founding Date
2015
Founding Date
2002
Type
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Tags
Locations
Locations
Incheon, KR HQ
Locations
Tübingen, DE HQ
Ottignies Louvain La Neuve, BE
Wiesbaden, DE
Amsterdam, NL
Basel, CH
Boston, US
Locations
Needham, US HQ
Locations
Écully, FR HQ
Cambridge, US
Locations
TW HQ
San Diego, US
Employees
Employees
6301% increase
Employees
999
Employees
50
Employees
432% decrease
Employees
124
Valuation ($)
Valuation ($)
N/A
Valuation ($)
648.3 m
Valuation ($)
176.8 m
Valuation ($)
N/A
Valuation ($)
N/A

Financial

Revenue (est.)
Revenue (est.)
₩2t (FY, 2022)
Revenue (est.)
€53.8m (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
NT$41.5m (FY, 2023)
Cost of goods
Cost of goods
₩1.4t (FY, 2022)
Cost of goods
€64.3m (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
NT$115m (FY, 2023)
Gross profit
Gross profit
₩664.7b (FY, 2022)
Gross profit
(€2.6m) (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Gross profit
(NT$63.8m) (FY, 2023)
Net income
Net income
₩147.2b (FY, 2022)
Net income
(€260.2m) (FY, 2023)
Net income
($37.9m) (FY, 2023)
Net income
N/A
Net income
(NT$1.3b) (FY, 2023)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 1.1b
Total funding raised
$ 64.6m
Total funding raised
$ 93.1m
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

CureVac
HQ
Tübingen, DE
Employees
999

CureVac is a biotechnology company offering messenger RNA (mRNA) technology.

View company
Candel Therapeutics
HQ
Needham, US
Employees
50

Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies.

View company
Amolyt Pharma
HQ
Écully, FR

Amolyt Pharma (formerly known as Alizé Pharma) is a company that specializes in the development of biopharmaceutical drugs, proteins, and peptides for the treatment of metabolic diseases and cancer.

View company
OBI Pharma
HQ
TW
Employees
124

OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics.

View company